유승열 (Moderna)님 | 한빛사연구자 > 한빛사

Moderna

최종업데이트 2025.08.18.

Elevated TIM3 expression on bone marrow T cells drives immune dysfunction in early relapsed blood cancer after allogeneic hematopoietic stem cell transplantation
- Exp. Hematol. Oncol., Aug 14 2025, 14 (1) 107 | https://doi.org/10.1186/s40164-025-00697-6
- 2025-08
- 의약학
- 한빛사논문
- 유승열(GeneDx, 현 Moderna)
Transcriptional regulatory network analysis identifies GRN as a key regulator bridging chemotherapy and immunotherapy response in small cell lung cancer
- J. Hematol. Oncol., Feb 05 2025, 18 (1) | https://doi.org/10.1186/s13045-025-01667-5
- 2025-02
- 생명과학
- 한빛사논문
Targeting ERRα promotes cytotoxic effects against acute myeloid leukemia through suppressing mitochondrial oxidative phosphorylation
- J. Hematol. Oncol., Published: 26 October 2022;15(1):156 | doi: 10.1186/s13045-022-01372-7
- 2022-10
- 의약학
- 한빛사논문
- 유승열(Sema4)
Integrative network analysis of early-stage lung adenocarcinoma identifies aurora kinase inhibition as interceptor of invasion and progression
- Nat. Commun., Published: 24 March 2022 | https://doi.org/10.1038/s41467-022-29230-7
- 2022-03
- 생명과학
- 한빛사논문

연구자 ID

저자논문